Retinitis Pigmentosa
Retinitis pigmentosa (RP) is a rare genetic eye disorder that causes progressive degeneration of the retina, leading to vision loss, particularly in low light conditions.
Retinitis Pigmentosa: GS030 Gene Therapy Study
We are evaluating a new gene therapy to see if it is safe and can improve vision in people with retinitis pigmentosa. Participants will receive a single injection and undergo light stimulation to assess potential benefits.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you between 18 and 75 years old?
- Do you have a diagnosis of non-syndromic retinitis pigmentosa (RP)?
- Are you currently pregnant or breastfeeding?
- Are you taking any medications that can affect your vision, like corticosteroids?
- Have you had any significant eye surgery in the past 3 months?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Gs030-Dp
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Quinze-Vingts National Ophthalmology Hospital
CIC 1423
Quinze-Vingts, France
Sponsor: Gensight Biologics
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.